DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

Clomiphene

Clomiphene interacts with estrogen receptors in the hypothalamus and pituitary, blocking estrogen-mediated negative feedback. This increases GnRH pulsatility and elevates pituitary secretion of LH and FSH. In women, the resulting FSH surge promotes follicular maturation and ovulation. In males, elevated LH stimulates Leydig cell testosterone production and elevated FSH supports spermatogenesis. The zuclomiphene (cis) isomer has a longer half-life and partial estrogen agonist activity, which contributes to the mixed agonist/antagonist profile of the racemic product.

Molecular Profile
small-molecule
10 AA Sequence
Evidence grade (Strong): Multiple randomized controlled trials in humans. This grade reflects the overall quality of available research on this compound and does not constitute a clinical recommendation.
CAS
911-45-5
Mol. weight
405.96 g/mol
Onset and duration

Injectable esters release over days to weeks depending on the ester; oral agents act within hours. Hormonal effects accrue over weeks, and dosing is individualized by a clinician.

Storage and reconstitution

Oral tablet; store at controlled room temperature in a dry place, protected from heat, light, and excessive moisture.

Clinical Evidence

What the literature says

Pharmacokinetics

Routes
Oral

Last reviewed: 2026-06-15

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Reported Uses

Key Research Benefits

Potential Side Effects

Ovarian hyperstimulation syndrome (OHSS) in women
Visual disturbances (blurring, scotomata; may be irreversible in rare cases)
Hot flashes and vasomotor symptoms
Abdominal discomfort or bloating
Multiple gestation risk (in women, not applicable to males)
Mood changes

Considerations and Cautions

  • Liver disease or impaired hepatic function
  • Abnormal uterine bleeding of undetermined cause (in women)
  • Uncontrolled thyroid or adrenal dysfunction
  • Ovarian cysts (in women)
  • Visual symptoms (history of visual field defects or optic neuritis)
  • Pregnancy

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

  • Estradiol (E2): SERM action affects estrogen signaling; monitoring guides estrogen balance.
  • LH and FSH: Primary pharmacodynamic endpoint; confirms gonadotropin response.
  • Lipid panel: SERMs affect lipid metabolism; baseline and periodic monitoring appropriate.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.